RE:Feline patent action for BOEHRINGER INGELHEIM ANIMAL HEALTH Thanks Pandora for following this stuff for the rest of us.
Interestingly, the September update noted the successful and significant extension of the anti-aging platform. I presume that is through modification of the patent to remain current for much longer periods of time.
I have confirmed with the company on several occasions that Sirona TFC-039 SGLT2 is at the centre of the pets deal, and I personally have confidence in their IP program here.
If you look at the next steps section on the September presentation, one can see that they are pursuing a potential use of the existing SGLT2 in a new market for humans. I am not certain what is going on there or what it means.